Merck & Co., Inc. stock (US58933Y1055): Key takeaways after latest Keytruda and oncology updates

Merck & Co., Inc. has reported new developments around its cancer drug Keytruda and other pipeline assets, while the stock reflects ongoing investor focus on the company’s post-patent-expiry strategy. This article highlights the latest catalysts and core business drivers for US investors.

Merck & Co., Inc. is back in the spotlight after a series of recent oncology and pipeline updates, including new data and regulatory developments around its blockbuster cancer drug Keytruda that continue to shape expectations for the company’s long?term growth beyond looming patent expiries. According to a company update on oncology and pipeline programs published in May 2026 on its investor relations site, Merck highlighted progress in several late?stage studies and regulatory interactions for Keytruda and other oncology assets, underlining the franchise’s central role in its strategy.Merck Investor Relations as of 05/2026 At the same time, recent commentary from management and industry reports shows investors paying close attention to how Merck plans to offset future revenue pressure once Keytruda faces biosimilar competition later in the decade.Reuters as of 04/2026

As of: 27.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, biotechnology, vaccines
• Headquarters/country: Kenilworth, New Jersey, United States
• Core markets: Global prescription medicines, vaccines and animal health, with a strong presence in the US market
• Key revenue drivers: Oncology (including Keytruda), vaccines, hospital acute care and animal health
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co., Inc.: core business model

Merck & Co., Inc. is a large, research?driven pharmaceutical company focused on discovering, developing, manufacturing and marketing prescription medicines, vaccines and animal health products. In its full?year 2024 results, which were reported in February 2025, Merck emphasized that oncology—especially the immuno?oncology drug Keytruda—remains its largest growth engine, complemented by vaccines such as Gardasil and pneumococcal products.Merck FY 2024 report as of 02/2025 The company’s business model combines high?margin innovative therapies with a diversified portfolio that also includes hospital acute care medicines and animal health offerings aimed at both companion animals and livestock.Merck company overview as of 03/2025

In the full?year 2024 earnings release, Merck reported that its pharmaceutical segment generated the majority of group revenue, with oncology and vaccines standing out as primary contributors during the 2024 reporting period.Merck FY 2024 earnings as of 02/2025 Management also highlighted R&D investment as a core element of the business, with spending focused on late?stage oncology, cardiometabolic and infectious disease programs, reflecting Merck’s aim to sustain innovation?driven growth over many years.Merck presentation as of 03/2025

Beyond branded human health products, Merck operates a sizable animal health division that offers vaccines, medicines and digital monitoring tools for livestock and pets. In its 2024 annual report released in early 2025, the company described animal health as a “resilient, cash?generative” business that provides diversification and relatively steady demand compared with more patent?dependent human medicines.Merck 2024 annual report as of 03/2025 This multi?pillar structure—oncology, vaccines, hospital products and animal health—helps balance cyclical and competitive pressures across different therapeutic categories.

From an operational standpoint, Merck sells its products worldwide through a combination of in?house sales teams, wholesalers, hospitals, government tenders and partnerships with other pharmaceutical companies. In its 2024 Form 10?K filed with the US Securities and Exchange Commission in February 2025, Merck noted that the United States remains its single largest market by revenue, underlining the importance of US pricing, reimbursement and healthcare policy dynamics to its financial performance.SEC Form 10?K as of 02/2025 At the same time, the company generates meaningful sales in Europe, Asia?Pacific and emerging markets, providing geographic diversification.

Main revenue and product drivers for Merck & Co., Inc.

Keytruda, Merck’s PD?1 inhibitor for multiple cancer indications, is the company’s flagship product and a central driver of revenue and investor attention. In its full?year 2024 earnings release, Merck reported double?digit sales growth for Keytruda compared with 2023, driven by strong adoption across lung cancer, melanoma and several additional tumor types over the 2024 reporting period.Merck FY 2024 earnings release as of 02/2025 The company continues to expand Keytruda’s label through new indications and combinations, and the recent oncology update in May 2026 highlighted further progress in late?stage trials aimed at strengthening its position in earlier?stage cancers and additional solid tumors.Merck oncology update as of 05/2026

Vaccines represent another major pillar of Merck’s revenue mix, with human papillomavirus vaccine Gardasil/Gardasil 9 and certain pediatric and adult vaccines among the leading contributors. In its 2024 results release published in February 2025, the company noted that Gardasil sales grew compared with 2023, supported by increased demand in both the US and key international markets during the 2024 financial year.Merck FY 2024 earnings release as of 02/2025 This vaccine franchise is seen as an important long?term asset because it is less exposed to near?term patent expiries and benefits from public health initiatives to protect against HPV?related cancers.CDC HPV vaccine information as of 01/2025

Merck’s hospital acute care and specialty products also contribute meaningfully to group sales. The company’s portfolio includes therapies for infectious diseases, cardiometabolic conditions and critical care, some of which are marketed under long?established brands. In the 2024 annual report, Merck highlighted that these products tend to generate stable revenue streams, although many face generic competition over time.Merck 2024 annual report as of 03/2025 To offset erosion in mature brands, Merck has focused on lifecycle management and incremental innovation, including new formulations, combinations and expanded indications where clinically justified.

The animal health segment, which sells vaccines and medicines for both food?producing animals and pets, is another key revenue driver. In its 2024 results communication, Merck reported that animal health revenue grew year?over?year, supported by demand for companion animal vaccines and parasiticides during the 2024 reporting period.Merck results communication as of 02/2025 Because veterinary products often have different competitive and regulatory dynamics compared with human medicines, this business can provide some insulation from patent cliffs in the pharmaceutical segment, which is an aspect that some investors view as strategically important.

In its May 2026 oncology and pipeline update, Merck also referenced ongoing clinical development for next?generation oncology agents and potential combinations intended to extend its leadership in immuno?oncology beyond Keytruda’s current patent life.Merck oncology update as of 05/2026 These include novel mechanisms, biomarker?driven approaches and collaborations with other companies. While individual trial outcomes remain uncertain, the breadth of late?stage programs is a core element of the company’s long?term revenue strategy.

Why Merck & Co., Inc. matters for US investors

Merck is one of the largest US?listed pharmaceutical companies and a long?standing component of major equity benchmarks, which makes its performance relevant for many diversified portfolios. Because the company is listed on the New York Stock Exchange under the ticker MRK and reports in US dollars, its earnings and cash flows are directly exposed to US pricing and reimbursement trends in oncology, vaccines and hospital drugs.NYSE MRK quote as of 05/2026 For US investors following the healthcare sector, Merck is often viewed as a bellwether for sentiment around large?cap pharmaceuticals and immuno?oncology.

At the same time, Merck’s strategy to manage the expected future loss of exclusivity for Keytruda is a central theme in analyst discussions and investor presentations. In recent conference remarks and slide decks made available in 2025 and 2026, the company stressed its intention to diversify earnings through vaccines, animal health and a deep late?stage pipeline to mitigate patent?expiry headwinds later in the decade.Merck strategy presentation as of 11/2025 For market participants, the pace at which new oncology indications, pipeline assets and business development deals translate into revenue is likely to influence how the stock trades relative to peers in the US pharmaceutical group.

Conclusion

Merck & Co., Inc. remains a major force in global pharmaceuticals, with Keytruda and vaccines such as Gardasil playing central roles in its revenue mix and strategic narrative. Recent oncology and pipeline updates in 2026 underscore the company’s efforts to extend its leadership in immuno?oncology while preparing for future patent expiries by advancing a broad late?stage portfolio and leveraging animal health and vaccines for diversification. For US investors, the stock offers exposure to large?cap healthcare dynamics, including innovation in cancer treatment, evolving US reimbursement frameworks and the execution risks around replacing blockbuster revenue over time, all of which will likely continue to influence how the market values Merck within the wider US and global equity landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.